Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)

BackgroundThyroid hormone impairment, represented as an alteration in levels of thyroid hormones and a lower fT3/fT4 ratio, has been correlated with a worse prognosis for both cancer and non-cancer patients. The role of baseline thyroid function in patients with metastatic renal cell carcinoma (mRCC...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marco Maruzzo, Elena Verzoni, Maria Giuseppa Vitale, Michele Dionese, Sebastiano Buti, Luca Galli, Andrea Zivi, Sara Watutantrige-Fernando, Teresa Zielli, Elisa Zanardi, Roberto Sabbatini, Umberto Basso, Vittorina Zagonel, Giuseppe Procopio
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	renal cell carcinoma FT3/FT4 deiodination tyrosine kinase inhibitors immunotherapy progression Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/9a3e4a93738845bf87bc0203274f79b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a3e4a93738845bf87bc0203274f79b2
record_format	dspace
spelling	oai:doaj.org-article:9a3e4a93738845bf87bc0203274f79b22021-11-30T22:56:46ZPrognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)2234-943X10.3389/fonc.2021.787835https://doaj.org/article/9a3e4a93738845bf87bc0203274f79b22021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.787835/fullhttps://doaj.org/toc/2234-943XBackgroundThyroid hormone impairment, represented as an alteration in levels of thyroid hormones and a lower fT3/fT4 ratio, has been correlated with a worse prognosis for both cancer and non-cancer patients. The role of baseline thyroid function in patients with metastatic renal cell carcinoma (mRCC) however, has not been studied yet.Materials and MethodsWe recorded clinical data, baseline biochemical results, and oncological outcomes from 10 Oncology Units in Italy. We stratified patients into three groups according to the fT3/fT4 ratio value and subsequently analyzed differences in progression-free survival (PFS) and overall survival (OS) in the three groups. We also performed univariate and multivariate analyses to find prognostic factors for PFS and OS.ResultsWe analyzed 134 patients treated with systemic treatment for mRCC. Median PFS in the low, intermediate, and high fT3/fT4 ratio group were 7.5, 12.1, and 21.7 months respectively (p<0.001); median OS in the three groups were 36.5, 48.6, and 70.5 months respectively (p =0.006). The low fT3/fT4 ratio maintained its prognostic role at the multivariate analysis independently from IMDC and other well-established prognostic factors. The development of iatrogenic hypothyroidism was not associated with a better outcome.ConclusionWe found that baseline thyroid hormone impairment, represented by a low fT3/fT4 ratio, is a strong prognostic factor in patients treated for mRCC in first line setting and is independent of other parameters currently used in clinical practice.Marco MaruzzoElena VerzoniMaria Giuseppa VitaleMichele DioneseMichele DioneseSebastiano ButiLuca GalliAndrea ZiviSara Watutantrige-FernandoTeresa ZielliElisa ZanardiRoberto SabbatiniUmberto BassoVittorina ZagonelGiuseppe ProcopioFrontiers Media S.A.articlerenal cell carcinomaFT3/FT4deiodinationtyrosine kinase inhibitorsimmunotherapyprogressionNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	renal cell carcinoma FT3/FT4 deiodination tyrosine kinase inhibitors immunotherapy progression Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	renal cell carcinoma FT3/FT4 deiodination tyrosine kinase inhibitors immunotherapy progression Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Marco Maruzzo Elena Verzoni Maria Giuseppa Vitale Michele Dionese Michele Dionese Sebastiano Buti Luca Galli Andrea Zivi Sara Watutantrige-Fernando Teresa Zielli Elisa Zanardi Roberto Sabbatini Umberto Basso Vittorina Zagonel Giuseppe Procopio Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)
description	BackgroundThyroid hormone impairment, represented as an alteration in levels of thyroid hormones and a lower fT3/fT4 ratio, has been correlated with a worse prognosis for both cancer and non-cancer patients. The role of baseline thyroid function in patients with metastatic renal cell carcinoma (mRCC) however, has not been studied yet.Materials and MethodsWe recorded clinical data, baseline biochemical results, and oncological outcomes from 10 Oncology Units in Italy. We stratified patients into three groups according to the fT3/fT4 ratio value and subsequently analyzed differences in progression-free survival (PFS) and overall survival (OS) in the three groups. We also performed univariate and multivariate analyses to find prognostic factors for PFS and OS.ResultsWe analyzed 134 patients treated with systemic treatment for mRCC. Median PFS in the low, intermediate, and high fT3/fT4 ratio group were 7.5, 12.1, and 21.7 months respectively (p<0.001); median OS in the three groups were 36.5, 48.6, and 70.5 months respectively (p =0.006). The low fT3/fT4 ratio maintained its prognostic role at the multivariate analysis independently from IMDC and other well-established prognostic factors. The development of iatrogenic hypothyroidism was not associated with a better outcome.ConclusionWe found that baseline thyroid hormone impairment, represented by a low fT3/fT4 ratio, is a strong prognostic factor in patients treated for mRCC in first line setting and is independent of other parameters currently used in clinical practice.
format	article
author	Marco Maruzzo Elena Verzoni Maria Giuseppa Vitale Michele Dionese Michele Dionese Sebastiano Buti Luca Galli Andrea Zivi Sara Watutantrige-Fernando Teresa Zielli Elisa Zanardi Roberto Sabbatini Umberto Basso Vittorina Zagonel Giuseppe Procopio
author_facet	Marco Maruzzo Elena Verzoni Maria Giuseppa Vitale Michele Dionese Michele Dionese Sebastiano Buti Luca Galli Andrea Zivi Sara Watutantrige-Fernando Teresa Zielli Elisa Zanardi Roberto Sabbatini Umberto Basso Vittorina Zagonel Giuseppe Procopio
author_sort	Marco Maruzzo
title	Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)
title_short	Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)
title_full	Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)
title_fullStr	Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)
title_full_unstemmed	Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)
title_sort	prognostic value of thyroid hormone ratio in patients with advanced metastatic renal cell carcinoma: results from the threefour study (meet-uro 14)
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/9a3e4a93738845bf87bc0203274f79b2
work_keys_str_mv	AT marcomaruzzo prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT elenaverzoni prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT mariagiuseppavitale prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT micheledionese prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT micheledionese prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT sebastianobuti prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT lucagalli prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT andreazivi prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT sarawatutantrigefernando prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT teresazielli prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT elisazanardi prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT robertosabbatini prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT umbertobasso prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT vittorinazagonel prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14 AT giuseppeprocopio prognosticvalueofthyroidhormoneratioinpatientswithadvancedmetastaticrenalcellcarcinomaresultsfromthethreefourstudymeeturo14
_version_	1718406218029989888

Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)

Ejemplares similares